About Sophie Rappel | Associate Director, Alliance Management, Genmab
Sophie joined Genmab in May 2023 as Associate Director, Alliance Management, and is located in the office in Utrecht, The Netherlands. Before joining Genmab, Sophie has been working in several Business Development & Alliance Management positions for 8 years. After obtaining her Master’s degree in Cancer, Stem cells and Developmental Biology at Utrecht University, she started her career at ProQR Therapeutics in Leiden (NL). There, she worked in BD & AM, where she was responsible for the transaction coordination of a clinical stage in-licensing deal with Ionis Pharmaceuticals, as well as the management of this alliance and several other academic collaborations. After ProQR, she joined the Business Development team of Intravacc B.V. (NL), where she was introduced to the world of vaccine development during the unique circumstance of the global pandemic.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX®, Arzerra, TEPEZZA®, Kesimpta® and DARZALEX FASPRO™. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies such as the DuoBody®, HexaBody® and the HexElect® platform. Genmab has alliances with top tier pharmaceutical and biotechnology companies and is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.
Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | |
|
© Copyright 2020 by Hyphen Projects